Clinical trials: PD-1 Inhibitors
HCC
Triple vs. Dual Adjuvant Therapy Following Liver Resection for HCC.
Vessels that encapsulate tumor clusters (VETC) is an invasive metastatic factor in HCC independent of the epithelial mesenchyme transition (EMT), and VETC-positive patients have a higher rate of postoperative recurrence.
- Trial name
- NCT06311942
- Testing
- HAIC plus PD-1 inhibitors plus lenvatinib, PD-1 inhibitors plus lenvatinib
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Chen Xiaoping
Melanoma
An Exploratory Study of Pembrolizumab Plus Entinostat in Non-Inflamed Stage III/IV Melanoma
Cancers develop in two different ways. First, cancer cells can become invisible to the immune system by stop having proteins on their surface that are required for the immune system to recognize them.
- Trial name
- NCT03765229
- Testing
- Entinostat, Pembrolizumab
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Primary Central Nervous System Lymphoma
Phase II Study of Orelabrutinib Combined With PD-1 Inhibitor in Relapsed/Refractory Primary Central Nervous System Lymphoma
This is a prospective multicenter single-arm phase II study, and the purpose of this study is to evaluate the efficiency of Orelabrutinib combined with PD-1 inhibitor regimen relapsed/refractory primary intraocular lymphoma.
- Trial name
- NCT04899427
- Testing
- orelabrutinib, Sintilimab, Tislelizumab
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Peking Union Medical College Hospital
Advanced Malignancies, Non-small-cell Lung Cancer
Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies
This is a Phase 1b/2 protocol to evaluate pharmacokinetics, safety, efficacy, and pharmacodynamics of PF-06801591, a programmed death-1(PD-1) antagonist monoclonal antibody (mAb) in participants with advanced malignancies.
- Trial name
- NCT04181788
- Testing
- PF-06801591
- Where
- 49 sites in China, Japan and 4 more
- Volunteers
- 155 people
- Sponsor
- Pfizer
Triple-Negative Breast Cancer
A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer
This study is a Phase 2, open-label,multicenter study designed to evaluate the efficacy and safety of 9MW2821monotherapy or combined with PD-1 inhibitor in locally advanced or metastatic Triple-Negative Breast Cancer.
- Trial name
- NCT06492005
- Testing
- 9MW2821, PD-1 inhibitior
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
Lung Diseases, Neoplasms
Sintilimab (IBI308) in the Neoadjuvant Treatment of Patients With Resectable II-IIIA NSCLC
The aim of this study was to investigate the safety and efficacy of Sintilimab (IBI308) in patients with resectable NSCLC, and to provide new treatment options for neoadjuvant therapy in patients with stage II-IIIA NSCLC
- Conditions
- Lung Diseases, Neoplasms, Respiratory Tract Diseases, Thoracic Neoplasms
- Trial name
- NCT04371796
- Testing
- Sintilimab injection
- Volunteers
- 20 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Esophageal Squamous Cell Carcinoma (ESCC)
Neoadjuvant Short-Course Radiotherapy Plus Tislelizumab and Chemotherapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
Neoadjuvant Short-Course Radiotherapy Followed by Tislelizumab Plus Chemotherapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma This is a prospective, randomized, two-arm, parallel-group, multicenter…
- Trial name
- NCT07678580
- Testing
- Albumin-bound paclitaxel, Low-dose Short-course Radiotherapy, High-dose Short-course Radiotherapy
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Tang-Du Hospital
Carcinoma, Small Cell, Lung Cancer
M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers
BACKGROUND: Small cell lung cancer (SCLC) is an aggressive cancer with a poor prognosis. Although highly responsive to chemotherapy initially, SCLC relapses quickly and becomes refractory to treatment within a few months.
- Conditions
- Carcinoma, Small Cell, Lung Cancer, Small Cell Lung Cancer
- Trial name
- NCT03554473
- Testing
- M7824, Topotecan, Temozolomide
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Esophageal Squamous Cell Carcinoma
Penpulimab Plus Chemotherapy With/Without Anlotinib for Patients With Advanced Esophageal Squamous Cell Carcinoma
Penpulimab plus chemotherapy with or without Anlotinib as first-line therapy for patients with advanced esophageal squamous cell carcinoma (Answer): A randomized two-arm clinical study.
- Trial name
- ANSWER (NCT05214222)
- Testing
- Anlotinib/Penpulimab/Chemotherapy, Penpulimab/Chemotherapy
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Tumor, Solid, Cancer, Metastatic
Phase I Study of SHR9146 + SHR-1210 +/- Apatinib in Patients With Advanced Solid Tumors
This phase I trial is designed to efficiently identify the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) for the combination therapy regimen of the IDO1 inhibitor SHR9146 when administered in combination with…
- Conditions
- Tumor, Solid, Cancer, Metastatic, Neoplasm Malignant
- Trial name
- NCT03491631
- Testing
- SHR9146+SHR-1210, SHR9146+SHR-1210+Apatinib
- Where
- China
- Volunteers
- 23 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Rectal Neoplasms Malignant, Radiotherapy
Short-course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer
This phase II/III trial studies how well neoadjuvant short-course radiotherapy and chemotherapy with or without PD-1 inhibitors works in treating patients with locally advanced rectal adenocarcinoma.
- Trial name
- NCT05484024
- Testing
- Sintilimab, Short-course radiotherapy, CAPOX/mFOLFOX
- Where
- 2 sites in China
- Volunteers
- 588 people
- Sponsor
- Chinese Academy of Medical Sciences
Gastric Junction Adenocarcinoma, Gastric Cancer
Safety and Efficacy Study of Sorbitol With Neoadjuvant Chemotherapy Combined With Tirellizumab (PD-1 Inhibitor) in Patients With Locally Advanced Gastric Cancer
The goal of this clinical trial is to learn if sorbitol works to enhance the therapeutic effect of neoadjuvant chemotherapy combined with Tirellizumab (PD-1 inhibitor) in patients with locally advanced gastric cancer.
- Conditions
- Gastric Junction Adenocarcinoma, Gastric Cancer, Immunotherapy, Neoadjuvant Therapies
- Trial name
- SNCCTGC (NCT06826079)
- Testing
- Sorbitol + PD-1 inhibitor + SOX chemotherapy, PD-1 inhibitor + SOX chemotherapy
- Where
- China
- Volunteers
- 86 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Oropharyngeal Cancer
PD-1 Inhibitor Based Induction Chemotherapy Followed by De-escalation Protocols in OPSCC
More and more studies have shown that the efficacy and prognosis of HPV （Human papillomavirus）-positive oropharyngeal cancer (OPC) patients are better than those of others.
- Trial name
- NCT06156891
- Testing
- Toxicities reduced treatment, Conventional treatment
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Fudan University
Advanced Malignant Solid Tumor
Neoantigen Reactive T Cells Combined With SHR-1210 for Chinese Patients With Advanced Refractory Solid Tumors
The purpose of this study is to see the safety and efficient of neoantigen reactive T cells (NRTs) combined with programmed cell death-1(PD-1) inhibitor（SHR-1210）in the treatment of Chinese patients with advanced refractory solid…
- Trial name
- NRT-01 (NCT03171220)
- Testing
- Neoantigen Reactive T Cells(NRTs), SHR-1210, Fludarabine
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Locally Advanced, Recurrent or Metastatic ESCC Patients Who Have Failed Prior PD-1/PD-L1 Inhibitors Combined With Platinum-based Chemotherapy
FH-006 Versus Investigator's Choice of Chemotherapy in Patients With Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma Who Have Failed Prior PD-1/PD-L1 Inhibitor Combined With Platinum-Based Chemotherapy.
The study compares the overall survival (OS) of FH-006 and the second-line chemotherapy selected by the investigators for treating esophageal squamous cell carcinoma patients.
- Trial name
- NCT07790380
- Testing
- FH-006, Paclitaxel, Docetaxel, Irinotecan
- Where
- China
- Volunteers
- 480 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Esophageal Cancer (EC)
A Phase II Study of Anlotinib + PD-1 Inhibitor vs. PD-1 Inhibitor Maintenance After First-Line Chemoimmunotherapy in Advanced ESCC (Esophageal Squamous Cell Carcinoma)
Chemotherapy combined with PD-1 inhibitor immunotherapy is the standard treatment for advanced esophageal squamous cell carcinoma (ESCC), yet patient prognosis remains unsatisfactory, with a median PFS of only about 6 months and…
- Trial name
- NCT07863141
- Testing
- anlotinib + PD-1 inhibitor, PD-1 inhibitor
- Where
- China
- Volunteers
- 112 people
- Sponsor
- Sun Yat-sen University
HR+HER2- Breast Cancer
Neoadjuvant Chemotherapy + PD-1 Inhibitor+Different Radiotherapy Fractionations for HR+/HER2- Breast Cancer
For the hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) subtype of breast cancer, although surgical, radiotherapy, and endocrine treatments have shown better survival, this subtype has a…
- Trial name
- NCT06639672
- Testing
- Chemotherapy+PD-1 inhibitor+8Gy x 3f, Chemotherapy+PD-1 inhibitor+16Gy x 1f, Chemotherapy+PD-1 inhibitor+2.67Gy x 15f
- Volunteers
- 60 people
- Sponsor
- Lei Liu
Gastric Cancer
Efficacy and Safety of Fruquintinib in Combination With PD-1 Inhibitors as First-line Maintenance Therapy for Advanced HER-2 Negative Gastric Cancer: a Single-arm, Prospective, Exploratory Clinical Study
Maintenance therapy is very important in advanced HER-2 negative gastric cancer, and immune monotherapy has no obvious benefit in the first-line maintenance treatment of advanced gastric cancer； Fruquintinib is a potent…
- Trial name
- NCT05721651
- Testing
- Fruquintinib+PD-1
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Wu Jun
Hepatocellular Carcinoma, Portal Vein Thrombosis
HAIC Combine With Lenvatinib and PD-1 Inhibitors for Advanced HCC With PVTT
The purpose of this study is to evaluate the safety and efficacy of hepatic arterial infusion chemotherapy combined with Lenvatinib and PD-1 inhibitors compared to Lenvatinib plus PD-1 inhibitors for advanced hepatocellular…
- Trial name
- NCT05166239
- Testing
- HAIC, Lenvatinib 1, PD-1 Inhibitors
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Peking University
Advanced Solid Tumors
ORIOn-E: A Study Evaluating CPI-1205 in Patients With Advanced Solid Tumors
This is a Phase 1/2, multi-center, open-label study of CPI-1205 + ipilimumab in patients with histologically or cytologically confirmed advanced solid tumors.
- Trial name
- NCT03525795
- Testing
- CPI-1205, ipilimumab
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Constellation Pharmaceuticals